Scarica l'app Stockscreener
3.67
4.86%
0.17
Dopo l'orario di chiusura:
3.67
Precedente Chiudi:
$3.50
Aprire:
$3.6
Volume 24 ore:
22,500
Relative Volume:
0.57
Capitalizzazione di mercato:
$369.24M
Reddito:
$68.15M
Utile/perdita netta:
$-67.60M
Rapporto P/E:
-5.4491
EPS:
-0.6735
Flusso di cassa netto:
$-41.80M
1 W Prestazione:
+1.10%
1M Prestazione:
-5.66%
6M Prestazione:
-27.18%
1 anno Prestazione:
+149.66%
Intervallo 1D:
$3.5701
$3.7581
Intervallo di 1 settimana:
$3.45
$3.80
Portata 52W:
$1.3271
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.67 | 352.14M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2022-05-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Robert W. Baird | Outperform |
| 2020-03-06 | Downgrade | Goldman | Neutral → Sell |
| 2019-10-30 | Ripresa | Guggenheim | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-05-24 | Ripresa | Citigroup | Neutral |
| 2019-03-14 | Iniziato | William Blair | Outperform |
| 2018-12-19 | Iniziato | Goldman | Neutral |
| 2018-07-16 | Iniziato | Barclays | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2017-09-05 | Downgrade | SunTrust | Buy → Hold |
| 2017-09-05 | Reiterato | Wells Fargo | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-02-28 | Iniziato | Wells Fargo | Outperform |
| 2016-04-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Iniziato | BofA/Merrill | Buy |
| 2015-04-20 | Iniziato | Jefferies | Buy |
| 2015-04-20 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Cellectis Adr Borsa (CLLS) Ultime notizie
CLLS Stock Price, Quote & Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Cellectis Reports Financial Results for the First Quarter 2026 - ChartMill
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - ChartMill
European ADRs Open Lower As Telecoms And Biotech Split - Finimize
Cellectis stock rating held at outperform on allogeneic platform - Investing.com
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - ChartMill
European ADRs Headed For A Strong Week In US Trading - Finimize
Monthly information on share capital and company voting rights - ChartMill
Citizens reiterates Cellectis stock rating on CAR-T progress - Investing.com
Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com
Earnings call transcript: Cellectis beats Q4 2025 forecasts, stock rises - Investing.com
Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - ChartMill
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill
European ADRs Slipped As Biopharma Dragged The Pack - Finimize
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com
European ADRs Started The Week Higher In US Trading - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets
Traders are paying attention to the gapping stocks in Monday's session. - ChartMill
Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com
Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets
European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm
Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com
European ADRs Stay Put As Novo Nordisk Slides - Finimize
Cellectis Adr Azioni (CLLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):